Araştırma Makalesi
BibTex RIS Kaynak Göster

Antibody Identity in Suspected Covid-19 Patients and Other Parameters

Yıl 2021, , 9 - 17, 28.02.2021
https://doi.org/10.33716/bmedj.861895

Öz

Aim: This study aimed to report laboratory findings of PCR and antibody research in suspect Covid-19 patients.
Materials and Methods: A total of 4206 patients with suspected Covid-19 and respiratory tract infection and 232 patients with mild clinical presentations such as cold who were admitted in hospitals were included in the study. After clinical examinations and radiological screenings, PCR tests of 4206 patients and antibody surveys of the 232 patients who were not hospitalized due to having only mild symptoms were carried out. For antibody detection, the plasmas of the EDTA-containing blood samples that were collected from the patients who were treated for Covid-19 and patients who were not treated due to having no symptoms or mild symptoms were separated and analyzed. The ‘Coronavirus disease IgM/IgG Rapid Test were used for the detection of antibodies. Antibody screenings were repeated three times 10, 17 and 24 days after the patients were diagnosed with Covid-19.
Results: The suspected Covid-19 were aged between 27 and 87 years and 2004 of the individuals were female (48%) and 2202 of the individuals were male (52%). Of 4206 plasma samples, 276 samples (6.56%) were RT-PCR-positive. Of the patients who had a positive PCR and were treated for Covid-19, 104 patients (37.68%) were female and 172 patients (62.32%) were male.
Conclusion: It is observed that death rates due to Covid-19 are more moderate in patients living in a cold climate and showing flu symptoms several times a year. Our study is in the form of some of the data of our region in order to shed light on future studies on this subject.

Destekleyen Kurum

-

Proje Numarası

-

Teşekkür

-

Kaynakça

  • 1. Cui J, Li F, Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol, 2019: 17;181–192.
  • 2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020; 24. doi:10.1001/jama.2020. 2648
  • 3. Kolb A.F, Hegyi A, Siddell S.G. Identification of residues critical for the human coronavirus 229E receptor function of human aminopeptidase N. J. Gen. Virol, 1997: 78; 2795–2802.
  • 4. Li W, Sui J, Huang I.C, Kuhn J.H, Radoshitzky S.R, Marasco W.A, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology, 2007: 367; 367–374.
  • 5. Hulswit R.J.G, Lang Y, Bakkers M.J.G, Li W, Li Z, Schouten A, Ophorst B, van Kuppeveld F.J, BoonsG.J, Bosch B.J. HumancoronavirusesOC43andHKU1bindto9-O acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc. Nat. Acad. Sci, 2019: 116; 2681–2690.
  • 6. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care, 2020: 24(1); 108.
  • 7. Coronavirus 2019-nCoV, CSSE. Coronavirus 2019-nCoV Global Cases by Johns Hopkins CSSE. (Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index. html#/bda7594740fd40299423467b48e9ecf6) (accession date 15.11.2020)
  • 8. Xu X.T, Chen P, Wang J.F, Feng J.N, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci.China Life Sci, 2020: 63(3); 457-460.
  • 9. 9.Ling Z, Xu X, Gan Q, et al. Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings. Eur J Radiol. 2020;126; 108956.
  • 10. McIntosh, Perlman S. Coronaviruses, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) In: Bennett JE, Dolin R, Blaser MJ (eds). Principles and Practice of Infectious Diseases. 8th edition. Philadelphia: Elsevier-Saunders, 2015: 1928-1936.
  • 11. Zhou P, Yang X.L, Wang X.G et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020: 579; 270-273.
  • 12. Wong A.C.P, Li X, Lau S.K.P, Woo P.C.Y. Global epidemiology of bat coronaviruses. Viruses, 2019 11;174.
  • 13. WHO. Disease outbreak news. Novel coronavirus—China, Jan 12, 2020. https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/ en/ (accessed Feb 11, 2020).
  • 14. 14.Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020: 8; 475-481.
  • 15. Corman V.M, Müller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infection. Euro Surveill, 2012: 6;17(49); .20334
  • 16. Türkiye Halk Sağlığı Kurumu Ulusal Mikrobiyoloji Standartları: Bulaşıcı Hastalıklar Laboratuvar Tanı Rehberi. TC Sağlık Bakanlığı Yayın No 934, Ankara, 2014
  • 17. Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for Middle East respiratory syndrome coronavirus (MERSCoV) - Version 2.1. http://www.cdc.gov/coronavirus/ mers/guidelines-clinical-specimens.html. accession date 01. 04.2020)
  • 18. Balkan Ç.E, Çelebi S. Doğu Anadolu Bölgesinde Şarbon Etkeni ve Seroprevalansının Araştırılması.Türk Mikrobiyol Cem Derg, 2018: 48(1); 52-59.
  • 19. Otter J.A, Donskey C, Yezli S, Douthwaite S, Goldenberg S.D, Weber D.J. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect, 2016: 92; 235-50
  • 20. Zaki A.M, van Boheemen S, Bestebroer T.M, Osterhaus A.D, Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012: 367; 1814-20.
  • 21. Phan L.T, Nguyen T.V, Luong Q.C, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med, 2020: 382; 72-874
  • 22. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020; 382:970-971.
  • 23. World Health Organization. Coronavirus disease (COVID-19) outbreak (https:// www .who .int). (accession date: 15.11.2020)
  • 24. Holshue M.L, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 2020: 382; 929-936.
  • 25. National Health Commission of the People’s Republic of China home page (http://www .nhc .gov .cn).( accession date:1 April 2020)
  • 26. Rodriguez-Morales A.J, Gallego V, Escalera-Antezana J.P, et al. COVID-19 in Latin America: the implications of the first confirmed case in Brazil. Travel Med Infect Dis, 2020: 35; .101613.

Covid-19 Şüphesi ile Başvuran Hastalarda Antikor Kimliği ve Diğer Parametreler

Yıl 2021, , 9 - 17, 28.02.2021
https://doi.org/10.33716/bmedj.861895

Öz

Amaç: Bu çalışma, şüpheli Covid-19 hastalarında PCR ve antikor araştırmalarının bulgularını değerlendirmeyi amaçlamaktadır.
Gereç ve Yöntemler: Çalışmaya Covid-19 ve solunum yolu enfeksiyonu şüphesiyle hastanemize başvuran toplam 4206 hasta ve soğuk algınlığı gibi hafif klinik semptomları olan 232 hasta dahil edildi. Klinik tetkikler ve radyolojik taramalar sonrasında 4206 hastanın PCR testleri ve sadece hafif semptomları nedeniyle hastaneye kaldırılmayan 232 hastanın ise antikor tetkikleri yapıldı. Antikor tespiti için Covid-19 tedavisi gören hastalardan ve hiçbir semptomu veya hafif semptomu olmadığı için tedavi edilmeyen hastalardan alınan EDTA içeren kan örneklerinin plazmaları ayrılarak analiz edildi. Antikorların tespiti için Covid-19 IgM / IgG Hızlı Test kiti kullanıldı. Antikor taramaları hastalara Covid-19 tanısı konulduktan 10, 17 ve 24 gün sonra üç kez tekrarlandı.
Bulgular: Şüpheli Covid-19 hastaları 27-87 yaşları arasındaydı. Bireylerin 2004'ü kadın (%48) ve 2202'si erkekti (%52). 4206 plazma örneğinden 276 örnek (%6,56) RT- PCR pozitifti. PCR pozitif olan ve Covid-19 tedavisi gören hastaların 104'ü (%37,68) kadın, 172'si (%62,32) erkek olarak saptandı.
Sonuç: Soğuk iklimde yaşayan ve gribal semptomları yıl içinde birkaç kez gösteren hastalarda Covid-19’ a bağlı ölüm oranlarının daha ılımlı seyrettiği görülmektedir. Çalışmamız bu konu hakkında gelecekte yapılacak çalışmalara ışık tutması amacıyla bölgemiz verilerinin bir kısmını yansıtmaktadır.

Proje Numarası

-

Kaynakça

  • 1. Cui J, Li F, Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol, 2019: 17;181–192.
  • 2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020; 24. doi:10.1001/jama.2020. 2648
  • 3. Kolb A.F, Hegyi A, Siddell S.G. Identification of residues critical for the human coronavirus 229E receptor function of human aminopeptidase N. J. Gen. Virol, 1997: 78; 2795–2802.
  • 4. Li W, Sui J, Huang I.C, Kuhn J.H, Radoshitzky S.R, Marasco W.A, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology, 2007: 367; 367–374.
  • 5. Hulswit R.J.G, Lang Y, Bakkers M.J.G, Li W, Li Z, Schouten A, Ophorst B, van Kuppeveld F.J, BoonsG.J, Bosch B.J. HumancoronavirusesOC43andHKU1bindto9-O acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc. Nat. Acad. Sci, 2019: 116; 2681–2690.
  • 6. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care, 2020: 24(1); 108.
  • 7. Coronavirus 2019-nCoV, CSSE. Coronavirus 2019-nCoV Global Cases by Johns Hopkins CSSE. (Available from: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index. html#/bda7594740fd40299423467b48e9ecf6) (accession date 15.11.2020)
  • 8. Xu X.T, Chen P, Wang J.F, Feng J.N, Zhou H, Li X, Zhong W, Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci.China Life Sci, 2020: 63(3); 457-460.
  • 9. 9.Ling Z, Xu X, Gan Q, et al. Asymptomatic SARS-CoV-2 infected patients with persistent negative CT findings. Eur J Radiol. 2020;126; 108956.
  • 10. McIntosh, Perlman S. Coronaviruses, including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) In: Bennett JE, Dolin R, Blaser MJ (eds). Principles and Practice of Infectious Diseases. 8th edition. Philadelphia: Elsevier-Saunders, 2015: 1928-1936.
  • 11. Zhou P, Yang X.L, Wang X.G et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020: 579; 270-273.
  • 12. Wong A.C.P, Li X, Lau S.K.P, Woo P.C.Y. Global epidemiology of bat coronaviruses. Viruses, 2019 11;174.
  • 13. WHO. Disease outbreak news. Novel coronavirus—China, Jan 12, 2020. https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/ en/ (accessed Feb 11, 2020).
  • 14. 14.Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, 2020: 8; 475-481.
  • 15. Corman V.M, Müller MA, Costabel U, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infection. Euro Surveill, 2012: 6;17(49); .20334
  • 16. Türkiye Halk Sağlığı Kurumu Ulusal Mikrobiyoloji Standartları: Bulaşıcı Hastalıklar Laboratuvar Tanı Rehberi. TC Sağlık Bakanlığı Yayın No 934, Ankara, 2014
  • 17. Centers for Disease Control and Prevention. Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for Middle East respiratory syndrome coronavirus (MERSCoV) - Version 2.1. http://www.cdc.gov/coronavirus/ mers/guidelines-clinical-specimens.html. accession date 01. 04.2020)
  • 18. Balkan Ç.E, Çelebi S. Doğu Anadolu Bölgesinde Şarbon Etkeni ve Seroprevalansının Araştırılması.Türk Mikrobiyol Cem Derg, 2018: 48(1); 52-59.
  • 19. Otter J.A, Donskey C, Yezli S, Douthwaite S, Goldenberg S.D, Weber D.J. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect, 2016: 92; 235-50
  • 20. Zaki A.M, van Boheemen S, Bestebroer T.M, Osterhaus A.D, Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012: 367; 1814-20.
  • 21. Phan L.T, Nguyen T.V, Luong Q.C, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med, 2020: 382; 72-874
  • 22. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020; 382:970-971.
  • 23. World Health Organization. Coronavirus disease (COVID-19) outbreak (https:// www .who .int). (accession date: 15.11.2020)
  • 24. Holshue M.L, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med, 2020: 382; 929-936.
  • 25. National Health Commission of the People’s Republic of China home page (http://www .nhc .gov .cn).( accession date:1 April 2020)
  • 26. Rodriguez-Morales A.J, Gallego V, Escalera-Antezana J.P, et al. COVID-19 in Latin America: the implications of the first confirmed case in Brazil. Travel Med Infect Dis, 2020: 35; .101613.
Toplam 26 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Klinik Tıp Bilimleri
Bölüm ARAŞTIRMA MAKALESİ
Yazarlar

Özgür Çelebi 0000-0003-4578-9474

Çiğdem Eda Balkan Bozlak 0000-0003-3922-7758

Sibel İba Yılmaz 0000-0002-4123-0828

Demet Çelebi 0000-0002-2355-0561

Proje Numarası -
Yayımlanma Tarihi 28 Şubat 2021
Yayımlandığı Sayı Yıl 2021

Kaynak Göster

APA Çelebi, Ö., Balkan Bozlak, Ç. E., İba Yılmaz, S., Çelebi, D. (2021). Antibody Identity in Suspected Covid-19 Patients and Other Parameters. Balıkesir Medical Journal, 5(1), 9-17. https://doi.org/10.33716/bmedj.861895